Survey
Quarterly Survey: ALS Treatments and Biogen's Qalsody (tofersen) October 2023
Ticker(s): BIIB, Mitsubishi Tanabe Pharma America, AMLXThe survey includes 20 neurological disease specialists.
How would you best describe your practice?
- Academic
- Community
- Private
- Other
How many of your ALS patients are on the following treatments today:
- Qalsody (tofersen)
- Relyvrio / AMX0035
- Radicava (edavarone)
How many of your ALS patients do you expect to be on the following treatments in the next 30 days:
- Qalsody (tofersen)
- Relyvrio / AMX0035
- Radicava (edavarone)
What percent (%) of your ALS patients do you expect to be on the following treatments in 1 year:
- Qalsody (tofersen)
- Relyvrio / AMX0035
- Radicava (edavarone)
How many of your patients with ALS started Qalsody (tofersen) for the first time in the last 30 days?
How many of your patients with ALS discontinued Qalsody (tofersen) in the last 30 days?
How would you rate Qalsody (tofersen) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
How would you rate Relyvrio/AMX0035 on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
How would you rate Radicava (edavarone) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
How does/will cost specifically impact access to Qalsody (tofersen) for patients with ALS?
In your opinion, how effective is Qalsody (tofersen) in treating ALS compared to other treatments? Please be specific.
What line of treatment would you consider Qalsody (tofersen) for patients with ALS?
Do you plan to increase your use of Qalsody (tofersen)?
Why or why not? Please be specific.
Please elaborate on your view of Qalsody (tofersen). Please be specific.
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Qalsody (tofersen) in treating ALS?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
